European Commission gives pharma, medtech industry opportunity for say on HTA network
This article was originally published in Clinica
The European Commission is seeking feedback from drug and medical device companies and other interested parties on creating a network of national health technology appraisal bodies, as outlined in the cross border healthcare directive. The commission's musings are general at this stage, but the consultation hints at areas that might affect the way that national HTA agencies work and how far industry and other stakeholders might be involved, says EUCOPE, the European Confederation of Pharmaceutical Entrepreneurs.
You may also be interested in...
Health technology assessment body NICE says that Revlimid fights cancer cells in a different way to current treatments which should help reduce resistance and improve disease outcomes.
The World Trade Organization is not the place to discuss pharmaceutical pricing, and strong intellectual property rights do not threaten access to medicines, according to EU and US delegations to the WTO.
Brazil’s medicines regulator, ANVISA, finally has a new set of rules for the evaluation and marketing authorization of advanced therapy medicines.